.png)
.png)
BIA regional focus: Cambridge
Moving and scaling: creating space for your growing life science company
Scaling up a company from a small initial lab to a larger operation carries a number of challenges, but key amongst these are the demands around finding, developing and using space to give yourself the room you need to achieve the next step of your company's journey. Join us at the Babraham Research Campus to hear from those who've made the transition in the past as they advise you on how best to tackle this challenge, and to network with other innovative life science companies around Cambridge.
12:00 Networking lunch
13:00 BIA update
13:10 Presentations and panel Q&A
14:00 Networking
Steve Bates OBE
What does your role at BIA involve?
Steve Bates is the CEO of the UK Bioindustry Association, the UK’s Trade Association for innovative life science companies with over 550 members. Steve is the visible face of the vibrant UK life sciences industry to government and media. He serves on the UK Government’s Life Sciences Council and the UK Biosecurity Leadership Council. Steve was a founder member of the UK Government’s Vaccine Taskforce in the Covid crisis, sitting on its steering Board alongside Kate Bingham. He is active member and former chair the International Council of Biotech Associations and has been a board member of EuropaBio since 2015.
Previous experience & achievements
Steve has championed, with government, effective industrial incentives like the Biomedical Catalyst, which have crowded in private sector investment into UK SMEs. He is a driving force behind the scale up agenda, spearheading policy agenda to unlock UK pension fund capital into productive UK growth in life sciences. He has forged several links for the sector across the USA, Europe and in China. In his time at the BIA, Steve has developed new member groups focused on cell and gene therapy, genomics and engineered biology. A strong advocate of partnership working, Steve champions sector collaboration with research charities and academia. Proud to lead an organisation with a diverse Board with over 40% female representation, Steve is committed to next generation talent and developing the skills needed for the sector to flourish. Before joining the BIA in 2012, Steve worked for Genzyme and was advisor to the UK Government of Tony Blair working on NHS reform and the Northern Ireland peace process. He was made OBE for services to innovation in 2017 and became a Fellow of the Academy of Medical Science in 2020.
Michael Skynner
Michael joined Bicycle Therapeutics in January 2016 to lead the discovery team and company operations as COO. As part of that role he oversaw the company move into new premises in 2017 at the Babraham Research Campus, and then again in 2022 into new facilities at the Portway, Granta Park. He switched into a new role as CTO in January 2022 to further accelerate Bicycle’s activities in therapeutic areas beyond Oncology. Prior to joining Bicycle, he lead Pfizer’s rare disease efforts in Europe and founded the Pfizer Rare Disease Consortium as well as Pfizer’s Genetic Medicine Institute, a bespoke research unit in central London embedded within the UK gene therapy academic community. Previously, he was VP and established a new Discovery Performance Unit (DPU) at GSK. Prior to GSK he co-founded a successful biotech start-up company, Cambridge Biotechnology Ltd. Here, he helped the company identify and occupy premises embedded within Cambridge University’s Pharmacology department and then into new facilities at the Babraham Research campus before a successful trade sale to Biovitrum, Swedish Orphan. Michael has over 22 years pharmaceutical and 5 years academic experience and obtained his PhD in Biochemistry at Imperial College in 1994.
Chris Walters
Chris leads the Life Science business at JLL that focuses on the science, technology and innovation sector. Through experience working with NHS Trusts; academic and research institutions; local authorities; and a diverse set of private sector clients covering private equity, institutional capital and sovereign wealth; Chris is recognised as an industry-leading expert on both the UK and European markets. Chris’s responsibilities are focused on providing strategic recommendations on a range of development and investment opportunities comprising development consultancy, appraisals and transactional advice. In addition, he works closely with all aspects of the occupier business to find tailored solutions to their needs across the full spectrum of the science and technology industry.
Ola Wlodek
After completing a PhD in Biology and Biomedical Sciences from Cambridge University in 2013, Ola worked in the several companies within the Cambridge cluster before joining Constructive Bio as CEO in July 2022. She is a currently an executive MBA candidate with the Warwick Business School.
Members Free
Non-members £30.00 +vat
By registering to this event you accept our Terms & Conditions
VENUE AND EVENT ACCESSIBILITY
We are regularly monitoring changes on government regulations around events. We recommend all attendees take a lateral flow test no more than 24 hours prior to the event. We advise any attendees who are not feeling well or who are displaying Covid-19 symptoms to please not attend.
Alternative or additional precautions like the wearing of masks inside the venue might also be considered and requested.
If you have any questions or problems registering, please contact Sam Care - [email protected]
Thank you to our event supporter
